Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

Completed · Phase 2

Conditions studied: Leukemia

In brief

The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.

Key facts

Study ID

NCT00083694

Run by

University of Arkansas

People needed

25

Starts

1998-08-01

Expected to finish

2005-05-01

Last updated by the study team

2010-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of refractory or relapsed leukemia: acute leukemia, CML, CLLm and MDS.
• Signed informed consent, including patient agreeing to use safe contraceptive methods during the treatment and for at least 4 months after the treatment is completed
• Serum creatinine < or = 2.5mg/dL
• Serum bilirubin< or = 2.5mg/dL
• Negative pregnancy test
• Age 18 years or older
• Performance status < or = 3

You may not qualify if…

• Pregnant or lactating women
• Concurrent treatment with cytotoxic chemotherapy, or radiation
• History of seizures, neurotoxicity, or active CNS disease
• Serious infections not controlled by antibiotics

Where it is running

• University of Arkansas for Medical Sciences/MIRT — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.